Skip to main content
OpenTrials
Completed

NCT Number: NCT02253173

Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vulvovaginal Atrophy Dyspareunia Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Diseases, Male Male Urogenital Diseases Menopause Mental Disorders Painful Intercourse Sexual Dysfunction, Physiological Sexual Dysfunctions, Psychological Urogenital Diseases

Age range

40 year–75 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Diex Research Montreal Inc., Montreal, Quebec, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Postmenopausal female subjects between the ages of 40 and 75 years (at the time of randomization) with at least:
  • 12 months of spontaneous amenorrhea (women <55 years of age with a history of hysterectomy without bilateral oophorectomy prior to natural menopause must have follicle stimulating hormone (FSH) levels > 40 mIU/mL), OR
  • 6 months of spontaneous amenorrhea with follicle stimulating hormone (FSH) levels > 40mlU/mL OR
  • At least 6 weeks postsurgical bilateral oophorectomy.
  • ≤5% superficial cells on vaginal cytological smear
  • Vaginal pH > 5.0
  • Moderate to severe symptom of vaginal pain associated with sexual activity considered the most bothersome vaginal symptom by the subject at screening visit 1A.
  • Moderate to severe symptom of vaginal pain associated with sexual activity at screening visit 1B.
  • Onset of moderate to severe dyspareunia in the postmenopausal years.
  • Subjects should be sexually active (i.e. have sexual activity with vaginal penetration within approximately 1 month of screening visit 1A).
  • Subjects should anticipate having sexual activity (with vaginal penetration) during the conduct of the trial.
  • For subjects with an intact uterus: Subjects must have an acceptable result from an evaluable screening endometrial biopsy.
  • Subjects who have a Body Mass Index (BMI) less than or equal to 38 kg/m2. BMI values should be rounded to the nearest integer (ex. 32.4 rounds down to 32, while 26.5 rounds up to 27).
  • In the opinion of the investigator, the subject will comply with the protocol and has a high probability of completing the study.

Exclusion criteria

  • Use of the following:
  • Oral estrogen-, progestin-, androgen-, or SERM-containing drug products within 8 weeks before screening visit 1A (can enter washout);
  • Use of transdermal hormone products within 4 weeks before screening visit 1A (can enter washout);
  • Use of vaginal hormone products (rings, creams, gels) within 4 weeks before screening visit1A (can enter washout);
  • Use of intrauterine progestins within 8 weeks before screening visit 1A (can enter washout);
  • Use of progestin implants/injectables or estrogen pellets/injectables within 6 months before screening visit 1A (cannot enter washout);
  • Use of vaginal lubricants or moisturizers within 7 days before the screening visit 1B vaginal pH assessment.
  • A history or active presence of clinically important medical disease that might confound the study or be detrimental to the subject, examples include:
  • Hypersensitivity to estrogens;
  • Endometrial hyperplasia;
  • Undiagnosed vaginal bleeding;
  • Have a history of a chronic liver or kidney dysfunction/disorder (e.g., Hepatitis C or chronic renal failure);
  • Thrombophlebitis, thrombosis or thromboembolic disorders;
  • Cerebrovascular accident, stroke, or transient ischemic attack;
  • Myocardial infarction or ischemic heart disease;
  • Malignancy or treatment for malignancy, within the previous 5 years, with the exception of basal cell carcinoma of the skin or squamous cell carcinoma of the skin. A history of estrogen dependent neoplasia, breast cancer, melanoma or any gynecologic cancer, at any time, excludes the subject;
  • Endocrine disease (except for controlled hypothyroidism or controlled non-insulin dependent diabetes mellitus).
  • Recent history of known alcohol or drug abuse.
  • History of sexual abuse or spousal abuse that, in the opinion of the PI, may interfere with the subject's assessment of vaginal pain with sexual activity.
  • Current history of Heavy smoking (more than 15 cigarettes per day) or use of e-cigarettes.
  • Use of an intrauterine device within 12 weeks before screening visit 1A.
  • Use of an investigational drug within 60 days before screening visit 1A.
  • Any clinically important abnormalities on screening physical exam, assessments, ECG, or laboratory tests, such as:
  • Unresolved cervical cytologic smear report of atypical glandular cells of undetermined significance (AGUS) or atypical squamous cells of undetermined significance (ASCUS).

Cervical cytologic smear report of low-grade squamous intraepithelial lesion (SIL) or greater, CIN1 or greater, or any reported dysplasia; Subjects with ASCUS are eligible only if high risk human papilloma virus (HPV) result is negative.

  • Unresolved findings suspicious for malignancy on the breast exam; incomplete mammogram result (BI-RADS 0) or unresolved findings suggestive of malignant changes or findings requiring short interval follow-up on the prestudy mammogram (subjects must have mammography result of BI-RADS 1 or 2 to enroll.) Mammogram may be performed within 9 months prior to Visit 2 (randomization) with documentation available. (The site must obtain a copy of the official report for the subject's study file, and it must be verified that the mammogram itself is available if needed for additional assessment);
  • In subjects with intact uterus: have a screening endometrial biopsy sample that is found by both primary pathologists to have endometrial tissue insufficient for diagnosis, no endometrium identified, or no tissue identified. (With the approval of the Medical Monitor, the screening endometrial biopsy may be repeated once);
  • In subjects with intact uterus: an endometrial biopsy report by one central pathologist at screening with one of the following:
  • Endometrial hyperplasia endometrial cancer, proliferative endometrium, weakly proliferative endometrium, disordered proliferative pattern; OR
  • Endometrial polyps with hyperplasia, glandular atypia of any degree (e.g., atypical nuclei) or cancer;
  • Vulvar or vaginal inflammatory condition such as a contact or allergic dermatitis, lichen sclerosis or other pathological findings;
  • Presence of suspicious vulvar or vaginal lesions for dysplasia, malignancy or other pathology other than atrophy;
  • Painful genital warts or localized areas of ulceration;
  • A history of active, chronic pelvic pain;
  • Interstitial cystitis;
  • Serum alanine aminotransferase (ALT) or serum aspartate aminotransferase (AST) greater than 1.5 times the upper limit of normal for the laboratory used;
  • Fasting total cholesterol greater than 300 mg/dL (7.77 mmol/L) or triglycerides greater than 300 mg/dL (3.39 mmol/L);
  • Fasting blood glucose greater than 125 mg/dL (6.94 mmol/L) with a hemoglobin A1C of greater than or equal to 6.5%;
  • Uncontrolled hypertension; subjects with elevated sitting blood pressure, greater than 140 mm Hg systolic or greater than 90 mm Hg diastolic and may not be using more than 2 antihypertensive medications for the treatment of hypertension;
  • Clinically significant abnormal 12-lead ECG (such as myocardial infarction or other findings suggestive of ischemia)
  • Be known to be pregnant or have a positive urine pregnancy test. (Note: A pregnancy test is not required for subjects who have had bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or are 55 years old or greater and have experienced cessation of menses for at least 1 year.
  • Current use of marijuana.

Treatment and study plan

Estradiol

Drug

Placebo

Drug

Primary outcomes

  1. Co-Primary Efficacy Endpoint - Vaginal Superficial Cells

    Time frame: Baseline and 12 Weeks

    • Change from Baseline to Week 12 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo

  2. Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells

    Time frame: Baseline and 12 Weeks

    • Change from Baseline to Week 12 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo

  3. Co-Primary Efficacy Endpoint - Vaginal pH

    Time frame: Baseline and 12 Weeks

    • Change from Baseline to Week 12 in vaginal pH as compared to placebo

  4. Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia)

    Time frame: Baseline and Week 12

    • Change from Baseline to Week 12 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo

    VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

    Subjects assessed severity at Baseline and Week 12

Secondary outcomes

  1. Secondary Efficacy Endpoints - Vaginal Superficial Cells

    Time frame: Baseline and Week 2

    • Change from Baseline to Week 2 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo

  2. Secondary Efficacy Endpoints- Vaginal Superficial Cells

    Time frame: Baseline and Week 6

    Change from Baseline to Week 6 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo

  3. Secondary Efficacy Endpoints - Vaginal Superficial Cells

    Time frame: Baseline and Week 8

    Change from Baseline to Week 8 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo

  4. Secondary Efficacy Endpoints - Vaginal Parabasal Cells

    Time frame: Baseline and Week 2

    Change from Baseline to Week 2 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo

  5. Secondary Efficacy Endpoints - Vaginal Parabasal Cells

    Time frame: Baseline and Week 6

    Change from Baseline to Week 6 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo

  6. Secondary Efficacy Endpoints - Vaginal Parabasal Cells

    Time frame: Baseline and Week 8

    Change from Baseline to Week 8 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo

  7. Secondary Efficacy Endpoints - Vaginal pH

    Time frame: Baseline and Week 2

    Change from Baseline to Week 2 in vaginal pH as compared to placebo

  8. Secondary Efficacy Endpoints - Vaginal pH

    Time frame: Baseline and Week 6

    Change from Baseline to Week 6 in vaginal pH as compared to placebo

  9. Secondary Efficacy Endpoints - Vaginal pH

    Time frame: Baseline and Week 8

    Change from Baseline to Week 8 in vaginal pH as compared to placebo

  10. Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)

    Time frame: Baseline and Week 2

    Change from Baseline to Week 2 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo

    VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

    Subjects assessed severity at Baseline and Week 2

  11. Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)

    Time frame: Baseline and Week 6

    Change from Baseline to Week 6 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo

    VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

    Subjects assessed severity at Baseline and Week 6

  12. Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)

    Time frame: Baseline and Week 8

    Change from Baseline to Week 8 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo

    VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

    Subjects assessed severity at Baseline and Week 8

  13. Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)

    Time frame: Baseline and Week 2

    Change from Baseline to Week 2 on the severity of vaginal dryness associated with VVA as compared to placebo

    VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

    Subjects assessed severity at Baseline and Week 2

  14. Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)

    Time frame: Baseline and Week 6

    Change from Baseline to Week 6 on the severity of vaginal dryness associated with VVA as compared to placebo

    VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

    Subjects assessed severity at Baseline and Week 6

  15. Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)

    Time frame: Baseline and Week 8

    Change from Baseline to Week 8 on the severity of vaginal dryness associated with VVA as compared to placebo

    VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

    Subjects assessed severity at Baseline and Week 8

  16. Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)

    Time frame: Baseline and Week 12

    Change from Baseline to Week 12 on the severity of vaginal dryness associated with VVA as compared to placebo

    VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

    Subjects assessed severity at Baseline and Week 12

  17. Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)

    Time frame: Baseline and Week 2

    Change from Baseline to Week 2 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo

    VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

    Subjects assessed severity at Baseline and Week 2

  18. Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)

    Time frame: Baseline and Week 6

    Change from Baseline to Week 6 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo

    VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

    Subjects assessed severity at Baseline and Week 6

  19. Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)

    Time frame: Baseline and Week 8

    Change from Baseline to Week 8 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo

    VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

    Subjects assessed severity at Baseline and Week 8

  20. Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)

    Time frame: Baseline and Week 12

    Change from Baseline to Week 12 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo

    VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.

    Subjects assessed severity at Baseline and Week 12

  21. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)

    Time frame: Baseline and Week 2

    Change from Baseline to Week 2 in Vaginal Color as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 2

  22. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)

    Time frame: Baseline to Week 6

    Change from Baseline to Week 6 in Vaginal Color as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 6

  23. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)

    Time frame: Baseline to Week 8

    Change from Baseline to Week 8 in Vaginal Color as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 8

  24. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)

    Time frame: Baseline and Week 12

    Change from Baseline to Week 12 in Vaginal Color as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 12

  25. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)

    Time frame: Baseline and Week 2

    Change from Baseline to Week 2 in Vaginal Epithelial Integrity as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3

    Severity was assessed by the Investigator at Baseline and Week 2

  26. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)

    Time frame: Baseline and Week 6

    Change from Baseline to Week 6 in Vaginal Epithelial Integrity as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3

    Severity was assessed by the Investigator at Baseline and Week 6

  27. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)

    Time frame: Baseline and Week 8

    Change from Baseline to Week 8 in Vaginal Epithelial Integrity as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3

    Severity was assessed by the Investigator at Baseline and Week 8

  28. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)

    Time frame: Baseline and Week 12

    Change from Baseline to Week 12 in Vaginal Epithelial Integrity as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3

    Severity was assessed by the Investigator at Baseline and Week 12

  29. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)

    Time frame: Baseline and Week 2

    Change from Baseline to Week 2 in Vaginal Epithelial Surface Thickness as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe [smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)] = 3

    Severity was assessed by the Investigator at Baseline and Week 2

  30. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)

    Time frame: Baseline and Week 6

    Change from Baseline to Week 6 in Vaginal Epithelial Surface Thickness as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe [smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)] = 3

    Severity was assessed by the Investigator at Baseline and Week 6

  31. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)

    Time frame: Baseline and Week 8

    Change from Baseline to Week 8 in Vaginal Epithelial Surface Thickness as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe [smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)] = 3

    Severity was assessed by the Investigator at Baseline and Week 8

  32. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)

    Time frame: Baseline and Week 12

    Change from Baseline to Week 12 in Vaginal Epithelial Surface Thickness as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe [smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)] = 3

    Severity was assessed by the Investigator at Baseline and Week 12

  33. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)

    Time frame: Baseline and Week 2

    Change from Baseline to Week 2 in Vaginal Secretions as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain) = 3

    Severity was assessed by the Investigator at Baseline and Week 2

  34. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)

    Time frame: Baseline and Week 6

    Change from Baseline to Week 6 in Vaginal Secretions as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain] = 3

    Severity was assessed by the Investigator at Baseline and Week 6

  35. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)

    Time frame: Baseline and Week 8

    Change from Baseline to Week 8 in Vaginal Secretions as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain] = 3

    Severity was assessed by the Investigator at Baseline and Week 8

  36. Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)

    Time frame: Baseline and Week 12

    Change from Baseline to Week 12 in Vaginal Secretions as compared to placebo

    Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain] = 3

    Severity was assessed by the Investigator at Baseline and Week 12

  37. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) - Total Score

    Time frame: Baseline and Week 12

    Change from Baseline to Week 12 in FSFI Total Score as compared to placebo

    The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

  38. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Arousal

    Time frame: Baseline and Week 12

    Change from Baseline to Week 12 in FSFI Domain Score (Arousal) as compared to placebo

    The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

  39. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Desire

    Time frame: Baseline and Week 12

    Change from Baseline to Week 12 in FSFI Domain Score (Desire) as compared to placebo

    The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

  40. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Lubrication

    Time frame: Baseline and Week 12

    Change from Baseline to Week 12 in FSFI Domain Score (Lubrication) as compared to placebo

    The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

  41. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Orgasm

    Time frame: Baseline and Week 12

    Change from Baseline to Week 12 in FSFI Domain Score (Orgasm) as compared to placebo

    The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

  42. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Pain

    Time frame: Baseline and Week 12

    Change from Baseline to Week 12 in FSFI Domain Score (Pain) as compared to placebo

    The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

  43. Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Satisfaction

    Time frame: Baseline and Week 12

    Change from Baseline to Week 12 in FSFI Domain Score (Satisfaction) as compared to placebo

    The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.

Other outcomes

  1. PK Substudy - Hormone Concentration Assessments (Serum Estradiol, Estrone and Estrone Conjugates; SHBG)

    Time frame: Pre-treatment, Day 2, Weeks 2 and 12

    Blood samples will be obtained from a subset of subjects at pre-selected sites to characterize PK parameters (AUC, tmax, Cmin, Cmax, Cavg) and to measure SHBG

Sponsors and collaborators

Lead sponsor

TherapeuticsMD

Industry

Registry information

Official study title

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Efficacy of TX-004HR in Postmenopausal Women With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy

Acronym: REJOICE

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Oct 1, 2014
Registry last updated
May 25, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.